An accessible multicenter, double-blind, randomized clinical trial of cerivastatin in patients with T2DM confirmed significantly lowered endogenous AGEs (by 21% after 12 weeks, CML was determined using ELISA assay) correlated with reduced LDL cholesterol and apolipoprotein B levels in all LDL subfractions, without effect on HbA1c [225]. This evidence concerns the gene APOB and type 2 diabetes mellitus.